Released Nov 7, 2024, after the close
10-Q filed Nov 7, 2024, 38 days after period end · 0000950170-24-123402
Q3 2024 · 10-Q
Revenue$6.85M$6.85M — vs Q3 2023−19.8% vs Q2 2024
Net Income-$9.61M-$9.61M N/M vs Q3 2023N/M vs Q2 2024
EPS Diluted-$1.51-$1.51 N/M vs Q3 2023N/M vs Q2 2024
Operating Income-$10,956,000N/M
Operating Cash Flowderived-$15,244,000N/M
Free Cash Flowderived-$15,244,000N/M
Margins · derived
Operating margin-160.1%
Net margin-140.4%
What the release said
The release
Same quarter
| Metric | Q3 2024 | Q3 2023 | Q3 2022 | Q3 2021 |
|---|---|---|---|---|
| Revenue | $6.85M | $0.00 | — | $6.25M |
| Net Income | -$9.61M | -$14.42M | -$23.15M | -$18.80M |
| EPS Diluted | -$1.51 | -$3.29 | -$0.48 | -$0.41 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Assembly Biosciences, Inc. · CIK 1426800 · Engraved from SEC EDGAR